Eliquis scores DVT/PE recommendation in Europe

Carly Helfand Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa ...

After multiple studies, MannKind finally wins an FDA OK for inhaled insulin Afrezza

John Carroll Three years and hundreds of millions of dollars after MannKind was handed its second FDA rejection on Afrezza, the third time proved the charm for the inhaled insulin. ...

Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly ...

Vertex could snag 250 more Kalydeco patients with EMA nod

Carly Helfand Back in February, the FDA green-lighted Kalydeco to treat cystic fibrosis in patients with one of 8 distinct gating mutations, dramatically ...

Concordia could be an inversion target; MiRagen re-ups with Servier;

Damian Garde FierceBiotech News

With Shire takeover bid, AbbVie looks to succeed where Pfizer failed

Carly Helfand AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire–the ...

Woodford buys $50M Prothena stake, Shire lacks ‘British gem’ status, French biotechs raise €100M

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on news that Neil Woodford's much-discussed fund is starting to take shape, with ...

UPDATE: Ranbaxy’s generic of Novartis blockbuster Diovan approved for launch

Eric Palmer The long-delayed and highly anticipated launch of generic Diovan is on the way, which is a bummer for Novartis and a huge boost for Indian drugmaker Ranbaxy Laboratories. ...

Report: Biopharma’s class of 2013 is laden with blockbusters

Damian Garde While 2013's number of approved drugs fell short of 2012's record haul, the class is likely to more than make up for that disparity in the dollar column, according ...

Sanofi tiptoes toward selling some older products

Carly Helfand Back in April, Sanofi was said to be considering some spring cleaning, weighing a sale of older products to make room for the bolt-on deals CEO Chris Viehbacher wants ...

UPDATED: FDA experts spurn AstraZeneca’s pitch for ovarian cancer drug olaparib

John Carroll AstraZeneca's top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA's panel of outside experts on Wednesday, ...

Reuters: Valeant supporter Paulson grabs 6 million-plus Allergan shares

Carly Helfand Tuesday, Valeant CEO J. Michael Pearson said his company was close to luring the 25% of Allergan investors it needs to call a special meeting, where it believes it can ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS